Preclinical data presented at AACR 2025 demonstrates ABP-102/CT-P72's superior tumor selectivity and reduced toxicity compared to existing HER2-targeted T-cell engagers.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.